NNC6019-0001

Phase 3Small molecule

Novo Nordisk

NNC6019-0001 is one of 66 small molecule programs targeting Heart Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Recruiting

Heart DiseaseActive, not recruiting

Heart FailurePhase 3

Active, not recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Phase 3

Recruiting

Heart DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

NNC6019-0001

Novo Nordisk

Phase 3

1 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

LCZ696

Novartis

Preclinical

15 5

Zemplar

Savaysa

Xifaxan

2 8

Zoloft

VViatris Specialty LLC

Preclinical

2 9

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Heart Failure

NCT06260709

Q2 2029

Phase 3Recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT07207811

Clinical

Trials by Indication[1]

Heart Disease1 trial

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05442047·105 enrolled

Heart Failure1 trial

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06260709·80 enrolled

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)1 trial

CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07207811·1,280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NNC6019-0001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NNC6019-0001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NNC6019-0001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

NNC6019-0001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Trials by Indication[1]

Heart Disease1 trial

Heart Failure1 trial

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)1 trial

References

Drug Info

Quick Facts

Related News